Short answer:
At the moment the U.S. FDA has not approved a generic version of Xarelto (rivaroxaban), and there is no firm date for when one will become available. Generics are typically cleared after the last of the drug’s patents and regulatory exclusivities expire, which for rivaroxaban is projected to be sometime in the mid‑2020s (roughly 2025‑2026). Because the exact expiration dates are still a bit fuzzy—and because the FDA requires a formal approval process—no official launch date has been set yet.
---
How the timeline works
| Step | What happens | Typical timing |
|------|--------------|----------------|
| Patent expiry | The last “composition‑of‑matter” patent (the core chemical) and the last formulation or method patents run out. | For rivaroxaban, the key patents on the active ingredient expired in 2018–2020; formulation and delivery‑related patents run until about 2025–2026. |
| Generic filing | A company submits an “Abbreviated New Drug Application” (ANDA) that shows the generic is bioequivalent to the brand. | Can be done at any time after the last patent expires, but the FDA typically waits until exclusivity periods (e.g., 5‑year exclusivity for the atrial‑fibrillation indication) have ended. |
| FDA review | The FDA evaluates the ANDA, may hold a “patent challenge” or “inter‑examiner review,” and ultimately issues a “priority review” or “full approval.” | Review can take 6–12 months after the application is accepted. |
| Market launch | Once approved, the generic is priced, marketed, and distributed. | Usually 3–6 months after approval. |
Because the last exclusivity period for Xarelto (the 5‑year “new‑indication” exclusivity for atrial‑fibrillation) is scheduled to expire in 2024, the earliest a generic could be approved in the U.S. would be late 2024 or early 2025, assuming a company files and the FDA clears the product promptly.
---
Current status
| Country | Status | Notes |
|---------|--------|-------|
| United States | No generic approved | Xarelto is still the sole product on the market. The brand’s patents and exclusivities have not yet fully expired. |
| Canada | Generic available | Several Canadian manufacturers already sell rivaroxaban at lower prices. |
| Europe | Generic available in many countries | In the EU, generics entered the market in 2023 after the primary patent expired. |
| Other markets | Variable | In many countries, generics are available, but availability depends on local patent law and regulatory approvals. |
---
What to do if you’re looking for a lower‑cost option
| Option | What you need to consider |
|--------|--------------------------|
| Generic in another country | You can purchase a generic from a country where it is approved, but you must check local regulations about importing prescription drugs. |
| Formulary or discount program | Check with your pharmacy or insurance; many insurers negotiate lower prices for brand‑name drugs, especially for chronic indications like atrial fibrillation. |
| Patient assistance | Xarelto has a patient support program that can help with copays and medication access. |
| Wait for FDA approval | Once a generic is FDA‑approved, prices usually drop 20–50 %. |
---
Bottom line
- No generic Xarelto is FDA‑approved yet.
- The earliest official launch could be in the **late‑2024 to early‑2025 range, contingent on the last patent and exclusivity expirations and the FDA’s review process.
- In many other countries, generic rivaroxaban is already available and can be a more affordable option if you have the ability to obtain it safely.
If you’re a patient or caregiver, it’s a good idea to talk with your prescriber or pharmacist about the possibility of a generic or a more affordable alternative while you wait for FDA approval.